News | December 13, 2025
Merck wins key EU backing to expand use of PAH Drug WINREVAIR
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Subscribe To Our Newsletter & Stay Updated
